X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28) 28
severe 5-fluorouracil-associated toxicity (19) 19
index medicus (16) 16
pharmacogenetics (16) 16
pharmacology & pharmacy (16) 16
dpd deficiency (14) 14
ivs14+1g-greater-than-a mutation (14) 14
dihydrouracil dehydrogenase - genetics (12) 12
fluorouracil (12) 12
oncology (12) 12
fluorouracil - adverse effects (11) 11
single nucleotide polymorphisms (11) 11
5-fluorouracil (10) 10
dihydropyrimidine dehydrogenase (10) 10
male (10) 10
aged (9) 9
cancer (9) 9
chemotherapy (9) 9
dihydropyrimidine dehydrogenase-deficiency (9) 9
female (9) 9
genotype (9) 9
mutation (9) 9
neoplasms - drug therapy (9) 9
adult (8) 8
advanced colorectal-cancer (8) 8
antimetabolites, antineoplastic - adverse effects (8) 8
dihydrouracil dehydrogenase - metabolism (8) 8
middle aged (8) 8
blood mononuclear-cells (7) 7
capecitabine (7) 7
dihydropyrimidine dehydrogenase gene (7) 7
fluorouracil - administration & dosage (7) 7
dpyd (6) 6
fluorouracil - pharmacokinetics (6) 6
medicine & public health (6) 6
pharmacokinetics (6) 6
toxicity (6) 6
antimetabolites, antineoplastic - pharmacokinetics (5) 5
antineoplastic agents - adverse effects (5) 5
cancer-patients (5) 5
cell lung-cancer (5) 5
fluorouracil - metabolism (5) 5
genetic aspects (5) 5
neoplasms - genetics (5) 5
pharmacogenomics (5) 5
pharmacology/toxicology (5) 5
severe 5-fluorouracil toxicity (5) 5
severe fluorouracil toxicity (5) 5
severe toxicity (5) 5
single nucleotide polymorphism (5) 5
acute lymphoblastic-leukemia (4) 4
antimetabolites, antineoplastic - administration & dosage (4) 4
dihydropyrimidine dehydrogenase deficiency - genetics (4) 4
dihydrouracil dehydrogenase (4) 4
familial pyrimidinemia (4) 4
gene (4) 4
health aspects (4) 4
high prevalence (4) 4
internal medicine (4) 4
original (4) 4
performance liquid-chromatography (4) 4
phenotype (4) 4
point mutation (4) 4
polymorphism (4) 4
alleles (3) 3
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - metabolism (3) 3
antineoplastic agents - pharmacology (3) 3
biomarkers (3) 3
care and treatment (3) 3
colorectal neoplasms - drug therapy (3) 3
colorectal-cancer patients (3) 3
deficiency (3) 3
dehydrogenases (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
dihydropyrimidine dehydrogenase deficiency (3) 3
dihydropyrimidine dehydrogenase deficiency - diagnosis (3) 3
dihydropyrimidine dehydrogenase-activity (3) 3
donor site (3) 3
drug therapy (3) 3
drugs (3) 3
enzymes (3) 3
fluoropyrimidines (3) 3
fluorouracil - analogs & derivatives (3) 3
fluorouracil - therapeutic use (3) 3
fluorouracil - toxicity (3) 3
genetic polymorphisms (3) 3
genetic research (3) 3
heterozygote (3) 3
metastatic colorectal-cancer (3) 3
neoplasms - enzymology (3) 3
neoplasms - metabolism (3) 3
oxidoreductases - genetics (3) 3
pharmacotherapy (3) 3
polymorphism, genetic (3) 3
polymorphism, single nucleotide (3) 3
pyrimidine metabolism (3) 3
research (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1639 - 1650
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 06/2011, Volume 16, Issue 6, pp. 820 - 834
Learning Objectives After completing this course, the reader will be able to: List currently identified candidate genes involved in phase I metabolism that are... 
Anticancer drugs | Drug transport | Oncology | Pharmacogenetics | Personalized medicine | Phase I metabolism | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | SEVERE 5-FLUOROURACIL-ASSOCIATED TOXICITY | HUMAN LIVER-MICROSOMES | CELL LUNG-CANCER | CYTIDINE-DEAMINASE GENE | HUMAN BLEOMYCIN HYDROLASE | BREAST-CANCER PATIENTS | MULTIDRUG-RESISTANCE GENE | SINGLE NUCLEOTIDE POLYMORPHISMS | RECEIVING ADJUVANT TAMOXIFEN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Pharmacogenetics - methods | Enzyme Inhibitors - metabolism | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Aryl Hydrocarbon Hydroxylases - genetics | Genotype | Treatment Outcome | Neoplasm Proteins - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Antineoplastic Agents - adverse effects | ATP-Binding Cassette Transporters - metabolism | Biomarkers | ATP Binding Cassette Transporter, Sub-Family B | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Polymorphism, Single Nucleotide | Neoplasm Proteins - genetics | Precision Medicine | Clinical Pharmacology | Opportunities for Patient-Tailored Anticancer Therapy
Journal Article
Internal and Emergency Medicine, ISSN 1828-0447, 8/2013, Volume 8, Issue 5, pp. 417 - 423
Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur).... 
Medicine & Public Health | Toxicity | Internal Medicine | Fluoropyrimidine chemotherapy | Dihydropyrimidine dehydrogenase (DPD) | T